A
29.91
0.04 (0.13%)
| Previous Close | 29.87 |
| Open | 29.81 |
| Volume | 330,592 |
| Avg. Volume (3M) | 1,563,627 |
| Market Cap | 3,604,753,152 |
| Price / Sales | 408.51 |
| Price / Book | 2.71 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -8,360.90% |
| Diluted EPS (TTM) | -3.00 |
| Quarterly Revenue Growth (YOY) | -55.60% |
| Total Debt/Equity (MRQ) | 0.45% |
| Current Ratio (MRQ) | 16.91 |
| Operating Cash Flow (TTM) | -355.32 M |
| Levered Free Cash Flow (TTM) | -245.73 M |
| Return on Assets (TTM) | -22.47% |
| Return on Equity (TTM) | -34.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Avidity Biosciences, Inc. | Bearish | Bullish |
AIStockmoo Score
0.1
| Analyst Consensus | 4.0 |
| Insider Activity | -2.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.10 |
|
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.17% |
| % Held by Institutions | 112.42% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Casdin Capital, Llc | 31 Mar 2025 | 2,045,000 |
| Polar Capital Holdings Plc | 31 Mar 2025 | 1,788,868 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 75.00 (Citigroup, 150.75%) | Buy |
| 75.00 (Chardan Capital, 150.75%) | Buy | |
| Median | 62.50 (108.96%) | |
| Low | 54.00 (B of A Securities, 80.54%) | Buy |
| Average | 63.88 (113.57%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 31.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wolfe Research | 17 Jun 2025 | 55.00 (83.88%) | Buy | 29.36 |
| Raymond James | 11 Jun 2025 | 65.00 (117.32%) | Buy | 32.01 |
| Barclays | 10 Jun 2025 | 59.00 (97.26%) | Buy | 33.62 |
| Citigroup | 10 Jun 2025 | 75.00 (150.75%) | Buy | 33.62 |
| B of A Securities | 09 Jun 2025 | 54.00 (80.54%) | Buy | 32.66 |
| Chardan Capital | 09 Jun 2025 | 75.00 (150.75%) | Buy | 32.66 |
| 09 May 2025 | 65.00 (117.32%) | Buy | 27.87 | |
| HC Wainwright & Co. | 12 May 2025 | 68.00 (127.35%) | Buy | 29.33 |
| Needham | 09 Apr 2025 | 60.00 (100.60%) | Buy | 24.80 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GALLAGHER KATHLEEN P. | - | 29.36 | -911 | -26,747 |
| Aggregate Net Quantity | -911 | |||
| Aggregate Net Value ($) | -26,747 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 29.36 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GALLAGHER KATHLEEN P. | Officer | 17 Jun 2025 | Automatic sell (-) | 911 | 29.36 | 26,747 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |